Returm to 2015 MSM Consortium Agenda
Theme 3: Multiscale Modeling for Optimal Disease Diagnosis/Treatment Applications
Goal: Share and discuss methods for developing and incorporating multiscale modeling into the advancement of disease diagnosis/treatment models to advance clinical therapies.
Objectives: The speakers will address the Theme 3 Goal with the following four objectives:
- Identify strategies required to successfully navigate barriers to incorporation of multiscale models into clinical diagnostic/therapeutic applications
- Describe and illustrate key examples of computational methods used to bridge multiple scales in development of the models
- Provide insight regarding the adoption of valid computational models by medical practitioners
- Describe challenges that need to be pursued
Charge to the speakers, Theme 3:
- In your field, what is the status of incorporating MSM models into clinical decision support?
- What are the challenges that need to be overcome to facilitate and accelerate implementation?
September 9, 2015
Theme 3
11:00 am – 12:30pm: Multiscale Modeling for Optimal Disease Diagnosis/Treatment Applications
Moderator: David Eckmann
11:00-11:10am Maciej Swat - Virtual-tissue computer simulations
11:10-11:20am Scott L. Diamond - Coarse graining data-driven cellular models in multiscale simulations
11:20-11:30am Gary An - The meaning of parameter space as related to clinical populations: lessons from the simulation of 80 million sepsis patients
11:30-11:40am Feilim Mac Gabhann - From proteins, viruses and cells to patient 9opulations: simulations of potential HIV cures
11:40-11:50am Jean-Marie C Bouteiller - Multiscale Modeling: A Valuable Asset for Therapeutics Development
11:50-12:00pm Don Bolser - Value of computational modeling in understanding human pulmonary defensive reflexes
12:00-12:30pm Discussion (Panel)
Questions and Comments from the Audience:
Please submit your questions and comments below in the following format:
(Full Name) - Your question and/or comment
********* Start of Questions and Comments **********